Tackling COVID-19

To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication, including:

•Biophysical binding assays to block S protein and ACE2 interaction.

•Enzymatic inhibition assays for Furin,  PLpro, Cathepsin L proteases and, coming soon, Mpro and TMPRSS2.

Contact us for fast support of your drug discovery project with the highest quality standards.

 

Latest News

15-Sep-2020 Change of Name

ProQinase rebranding into Reaction Biology Europe GmbH As of September 08, 2020, we have started to operate under the name of Reaction Biology Europe GmbH. As this only represents a change of name, all contracts with us remain valid and binding. ProQinase...

Newsletter

Stay informed/Get special offers